ArticleClinical & experimental metastasis2008
Bone resorption increases tumour growth in a mouse model of osteosclerotic breast cancer metastasis.
Article in Clinical & experimental metastasis, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 45 citations in OpenAlex.
- Dynamic changes of Receptor activator of nuclear factor-κB expression in Circulating Tumor Cells during Denosumab predict treatment effectiveness in Metastatic Breast Cancer.Scientific reports · 2020Trial
- The anti-tumor agent sagopilone shows antiresorptive effects both in vitro and in vivo.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2011Trial
- Bone niches in the regulation of tumour cell dormancy.Journal of bone oncology · 2024Article
- Osteoblasts and osteoclasts: an important switch of tumour cell dormancy during bone metastasis.Journal of experimental & clinical cancer research : CR · 2022Review
- The Osteoclast Traces the Route to Bone Tumors and Metastases.Frontiers in cell and developmental biology · 2022Review
- Review
- Tumor Cell Dormancy and Reactivation in Bone: Skeletal Biology and Therapeutic Opportunities.JBMR plus · 2019Review
- Emerging and Established Models of Bone Metastasis.Cancers · 2018Review
- The vitamin D receptor is involved in the regulation of human breast cancer cell growth via a ligand-independent function in cytoplasm.Oncotarget · 2017Article
- Loss of the vitamin D receptor in human breast and prostate cancers strongly induces cell apoptosis through downregulation of Wnt/β-catenin signaling.Bone research · 2017Article
- Cancer Cell Colonisation in the Bone Microenvironment.International journal of molecular sciences · 2016Review
- RANK-RANKL signalling in cancer.Bioscience reports · 2016Review
- Bone metastasis: the importance of the neighbourhood.Nature reviews. Cancer · 2016Review
- An improved intrafemoral injection with minimized leakage as an orthotopic mouse model of osteosarcoma.Analytical biochemistry · 2015Article
- Targeting IL-6 and RANKL signaling inhibits prostate cancer growth in bone.Clinical & experimental metastasis · 2014Article
- A tissue-engineered humanized xenograft model of human breast cancer metastasis to bone.Disease models & mechanisms · 2014Article
- The role of the bone microenvironment in skeletal metastasis.Journal of bone oncology · 2013Review
- Article
- Reversal of chemotherapy-induced leukopenia using granulocyte macrophage colony-stimulating factor promotes bone metastasis that can be blocked with osteoclast inhibitors.Cancer research · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteosclerotic metastases account for 20% of breast cancer metastases with the remainder osteolytic or mixed. In mouse models, osteolytic metastases are dependent on bone resorption for their growth. However, whether the growth of osteosclerotic bone metastases depends on osteoclast or osteoblast actions is uncertain. In this study, we investigate the effects of high and low bone resorption on tumour growth in a mouse model of osteosclerotic metastasis. We implanted human breast cancer, MCF-7, cells into the tibiae of mice. Low and high levels of bone resorption were induced by osteoprotegerin (OPG) treatment or calcium deficient diet respectively. We demonstrate that OPG treatment significantly reduces tumour area compared to vehicle (0.42 +/- 0.06 vs. 1.27 +/- 0.16 mm2, P < 0.01) in association with complete inhibition of osteoclast differentiation. In contrast, low calcium diet increases tumour area compared to normal diet (0.90 +/- 0.30 vs. 0.58 +/- 0.20 mm2, P < 0.05) in association with increased osteoclast numbers (84.44 +/- 5.18 vs. 71.11 +/- 3.56 per mm2 bone lesion area, P < 0.05). Osteoblast surfaces and new woven bone formation were similarly increased within the tumour boundaries in all treatment groups. Tumour growth in this model of osteosclerotic metastasis is dependent on ongoing bone resorption, as has been observed in osteolytic models. Bone resorption, rather than bone formation, apparently mediates this effect as osteoblast surfaces in the tumour mass were unchanged by treatments. Treatment of breast cancer patients through correction of calcium deficiency and/or with anti-resorptive agents such as OPG, may improve patient outcomes in the adjuvant as well as palliative settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.